Top Feature - Pharmaceutical Executive


Top Feature

2015 Pipeline Report: Burning Bright

November 1, 2014

The science of drug discovery is back on script—and the stars are cued up for a new generation of breakthrough therapies. But is pharma ready to raise its game and cut a deal with all those "prove it to me" payers?

Oschmann Outlines Next Two years as IFPMA President, Raises Ire on IP

November 11, 2014

Merck KGaA CEO Stefan Oschmann spoke last week in New York as he accepted the two-year role as president of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA).

Gaps in Global Standards Threaten Biosimilars Development

September 29, 2014

Although progress has been made in bringing biosimilars to market, gaps in requirements for testing and documenting product similarity are still hampering the EU, U.S., and other regions, writes Jill Wechsler.

Eruptions on Europe's Drug-Pricing Horizon

September 22, 2014

The EU may have a new monitoring scheme for Iceland's volatile geology, but it should also heed the volcano that could blow apart its assumptions on drug pricing and reimbursement, says Reflector.

French Connections

July 31, 2014

The Galien Foundation and the French government investment agency UBIFRANCE have partnered to establish UBISTART, a transatlantic payout for the best in start-up innovations. William Looney reports.

FDA Abroad

July 21, 2014

FDA officials willing to relocate to far-flung global cities should be congratulated for their herculean efforts to protect American patients. But funding cuts hamper the Agency's international presence.

Pharm Exec's 2014 Dealmakers Outlook

July 10, 2014

As the pacing picks up around dealmaking as the alternative to organic growth, Pharm Exec brings together experts from big Pharma and biotech to dissect the road ahead for M&A, licensing, and partnership activity.

Capturing the Real Value from a Pharma Spinout

July 9, 2014

The pharma spin market is moving up a gear as companies see the imperative to tap into brand value. Allen Gove explains how understanding what the company is about is critical to bolstering the value of the product.

The Graying of Clinical Trials

June 4, 2014

Elderly patients are underrepresented in clinical trials, but there are few obstacles to including this patient group in trials that cannot be overcome, writes Sydney Rubin.


Click here